Powering the microbiome with synthetic biotics
Profile Provided By: Company Website
Synlogic Inc. a biopharmaceutical company offers synthetic biotics that perform specific metabolic functions from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It provides SYNB1010 for urea cycle disorder a synthetic biotic that is designed to remove excess ammonia from the blood and SYNB2010 for phenylketonuria a synthetic biotic that is designed to remove excess phenylalanine from the blood. The company was formerly known as TMC Therapeutics Inc. and changed its name to Synlogic Inc. in March 2014. Synlogic Inc.
|Human health & social work||Operating||11 - 50 employees|
Funding and Financing Rounds
Feb, 2016 / $40M / Series B
Oct, 2014 / $5M / Series A / PRI / Equity
Jul, 2014 / $29,4M / Series A / PRI
- Social Policies and Performance
Impact Reports & Metrics
200 Sidney St.
Cambridge, Massachusetts 02139
United States of America